Brief: Sensei Biotherapeutics Announces Prioritization Of Next-Generation Multi-Antigenic Immunophage Platform

Faeth Therapeutics,

28/06/2021 21:51

June 28 (Reuters) - Sensei Biotherapeutics Inc  SNSE.O :
    * SENSEI BIOTHERAPEUTICS ANNOUNCES PRIORITIZATION OF
NEXT-GENERATION MULTI-ANTIGENIC IMMUNOPHAGE PLATFORM, MONOCLONAL
ANTIBODY AND NANOBODY PROGRAMS
    * SENSEI BIOTHERAPEUTICS INC - EXPECTS ITS CASH AND CASH
EQUIVALENTS WILL BE SUFFICIENT TO FUND ITS OPERATIONS INTO FIRST
HALF OF 2024.
    * SENSEI BIOTHERAPEUTICS INC - COMPANY TO FOCUS ON
DEVELOPMENT OF
NEXT-GENERATION PHAGE PRODUCT CANDIDATES FROM IMMUNOPHAGE
PLATFORM
    * SENSEI BIOTHERAPEUTICS - LOOK FORWARD TO INITIATING
IND-ENABLING
STUDIES FOR SNS-VISTA BY END OF 2021 AND FOR SNS-401-NG IN
SECOND HALF OF 2022

Source text for Eikon:  ID:nGNX5F2hDm 
Further company coverage:  SNSE.O 

 ((Reuters.Briefs@thomsonreuters.com;))